VLTR 751
Alternative Names: VLTR-751Latest Information Update: 20 Oct 2022
At a glance
- Originator Valitor
- Class Drug conjugates; Eye disorder therapies
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Uveitis
Most Recent Events
- 13 Oct 2022 Preclinical trials in Uveitis in USA (Valitor pipeline, October 2022)